Biostax (BTAX) 10-K 18 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 18, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-54933
Entity Registrant Name	IMMUNE THERAPEUTICS, INC.
Entity Central Index Key	0001559356
Entity Tax Identification Number	59-3226705
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2431 Aloma Ave.
Entity Address, Address Line Two	Suite 124
Entity Address, City or Town	Winter Park
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32792
City Area Code	888
Local Phone Number	613-8802
Title of 12(b) Security	Common stock
Trading Symbol	IMUN
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 2,387,600
Entity Common Stock, Shares Outstanding		483,714
ICFR Auditor Attestation Flag	false
Auditor Firm ID	76
Auditor Name	Turner, Stone & Company, L.L.P
Auditor Location	Dallas, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 493,885	$ 9,971
Equity securities at fair value	2,645,000
Total current assets	3,138,885	9,971
Deposits		200
Total Assets	3,138,885	10,171
Current Liabilities:
Accounts payable	2,184,848	2,562,515
Accrued payroll	3,421,176	3,627,648
Notes payable, net of debt discount	3,070,208	2,844,851
Net due to related parties	891,420	531,420
Undocumented investor advances	715,631
Accrued interest	564,300	635,217
Accrued liabilities	239,558	221,057
Derivative liability		1,254,444
Total current liabilities	11,087,141	11,677,152
Total Liabilities	11,087,141	11,677,152
Commitments and Contingencies
Stockholders’ Deficit:
Common stock – par value $0.0001; 750,000,000 and 500,000,000 shares authorized, respectively; 483,714 and 476,504 shares issued and outstanding respectively	49	48
Additional paid in capital	371,473,810	371,341,120
Stock issuances due	10,303	10,303
Accumulated deficit	(379,432,418)	(383,018,452)
Total stockholders’ deficit	(7,948,256)	(11,666,981)
Total Liabilities and Stockholders’ Deficit	$ 3,138,885	$ 10,171

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	500,000,000
Common stock, shares issued	483,714	476,504
Common stock, shares outstanding	483,714	476,504

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues, net
Cost of products sold
Gross profit
Operating expenses:
Selling, general and administrative	585,502	760,132
Research and development expense	152,667	126,259
Depreciation and amortization expense		639
Total operating expenses	738,169	887,030
Loss from operations	(738,169)	(887,030)
Other income (expense):
Interest expense	(210,919)	(479,931)
Receipt of common shares	5,761,500
Change in market value of common shares	(3,116,500)
Gain on settlement of debt and liabilities	711,892	3,502,280
Gain (loss) on valuation of derivative	1,178,230	(373,584)
Finance charges		(173,118)
Total other income	4,324,203	2,475,647
Net income	$ 3,586,034	$ 1,588,617
Basic earnings per share attributed to common stockholders	$ 7.43	$ 3.44
Diluted earnings per share attributed to common stockholders	$ 0.38	$ 0.11
Weighted average number of shares outstanding	9,394,164	16,016,427
Basic weighted average number of shares outstanding	482,826	461,190

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock to be Issued [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 46	$ 370,908,099	$ 10,303	$ (384,607,069)	$ (13,688,621)
Beginning balance, shares at Dec. 31, 2019	457,578
Issuance of common stock upon conversion of debt	$ 2	152,638			152,640
Issuance of common stock upon conversion of debt, shares	18,926
Extinguishment of derivative liability upon conversion of debt		280,383			280,383
Net income				1,588,617	1,588,617
Ending balance, value at Dec. 31, 2020	$ 48	371,341,120	10,303	(383,018,452)	(11,666,981)
Ending balance, shares at Dec. 31, 2020	476,504
Issuance of common stock upon conversion of debt	$ 1	56,479			56,480
Issuance of common stock upon conversion of debt, shares	5,402
Extinguishment of derivative liability upon conversion of debt		76,211			76,211
Effect of fractional shares upon reverse stock split
Effect of fractional shares upon reverse stock split, shares	1,808
Net income				3,586,034	3,586,034
Ending balance, value at Dec. 31, 2021	$ 49	$ 371,473,810	$ 10,303	$ (379,432,418)	$ (7,948,256)
Ending balance, shares at Dec. 31, 2021	483,714

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 3,586,034	$ 1,588,617
Adjustments to reconcile net loss to net cash flows used in operating activities:
Gain recognized upon receipt of equity securities	(5,761,500)
Change in market value of equity securities	3,116,500
Gain on settlement of debt and liabilities	(711,892)	(3,502,280)
Change in value of derivative liability	(1,178,230)	373,584
Amortization of debt discount	34,790	162,210
Non-cash finance charge		173,118
Depreciation		639
Changes in operating assets and liabilities:
Deposits	200
Accounts payable	103,752	99,233
Accrued payroll	24,000	16,838
Accrued interest	176,131	327,883
Accrued liabilities	18,498	85,000
Due to related parties	360,000	483,203
Net cash used in operating activities	(231,717)	(191,955)
CASH FLOWS FROM INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from undocumented investor advances	715,631
Proceeds from issuance of notes (net)		197,000
Net cash provided by financing activities	715,631	197,000
Increase in cash	483,914	5,045
Cash and cash equivalents, beginning of year	9,971	4,926
Cash and cash equivalents, end of year	493,885	9,971
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of accrued interest to notes payable	243,568
Conversion of notes and accrued interest to common stock	56,480	152,640
Debt discounts on notes payable and warrants		$ 197,000

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Company Overview Immune Therapeutics Inc. (the “Company” or “IMUN”) is a Florida Public Company trading on the OTC-Pink. The Company has been inactive for the last year due to a lack of funding, and with the Company’s current structure, it is impossible to move forward until a restructuring of the Company is completed. Going Concern As of December 31, 2021, the Company had $ 493,885 in cash on hand, negative working capital of $ 7,948,256 and a stockholders’ deficit of $ 7,948,256 . For the year ended December 31, 2021, the Company reported net income attributable to common shareholders of $ 3,586,034 . Net income for the twelve-month period ended December 31, 2021 includes significant non-cash non-operating gains and (losses) aggregating $ 4,535,122 as follows: Schedule of Income Statement Gain on settlement of debt and liabilities $ 711,892 Receipt of common shares 5,761,500 Change in market value of common shares (3,116,500 ) Gain on reversal of derivative liability 1,178,230 Non-operating gains $ 4,535,122 For the year ended December 31, 2020, the Company reported net income attributable to common shareholders of $ 1,588,617 3,502,280 Historically the Company has relied on the funding of operations through private equity financings and management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of product candidates as they become available and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Working capital at December 31, 2021 is not sufficient to meet the cash requirements to fund planned operations through the next twelve months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. Management is developing as a strategy to re-capitalize the Company and position it for future growth. Key steps to this process include: ● Improve the condition of the balance sheet via license arrangements and capital infusions ● Identify and acquire late-stage assets for commercialization ● Build out operational infrastructure to generate revenue opportunities to grow shareholder value. There can be no guaranties that the Company will be successful in securing adequate capital to continue operations and in identifying and acquiring assets for future development. If the Company is unable to secure new working capital, other alternatives strategies will be required. Historically, the Company has been able to acquire and develop assets, spin them out and retain both an equity stake and royalties and milestone payments. In so doing, the Company has acted as an incubator for late-stage drug development. Management believes that this strategy can continue to be successful. At this time, the Company is reviewing several opportunities which it may pursue as soon as funding is available. At present no definitive actions have been taken. There can be no guaranties that the Company will be successful in: ● Executing its restructuring plan ● Securing adequate capital to continue operations. ● Identifying and acquiring assets for future development. Company History Immune Therapeutics, Inc. (“the Company”, “Immune”) was initially incorporated in Florida on December 2, 1993, as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014, changing our name to Immune Therapeutics, Inc. The consolidated financial statements of the Company include the following inactive subsidiaries: (1) TNI BioTech, Ltd., a BVI company in Tortola, British Virgin Islands incorporated in October 2012 which was set up to market and sell Naltrexone outside the United States, (2) TNI BioTech, LTD, United Kingdom incorporated in August 2013 which was set up as a micro, small or medium-sized enterprise to be able to sell administrative and financial assistance programs offered by European Medicines Agency, (3) Airmed Biopharma Limited, Dublin Ireland incorporated in March 2014 which was set up to qualify for tax incentives for Irish holding/headquartered companies to benefit from the network of double tax treaties that reduce withholding taxes and (4) Airmed Holdings Limited an Irish company domiciled in Bermuda incorporated in March 2014 set up to manage international distribution.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“GAAP”) and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000 Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of the Company’s investment in the common stock of Statera BioPharma (“STAB”) is measured based on the quoted per share price as reported on NASDAQ and is a level 1 asset. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes. Derivative Financial Instruments FASB ASC 815, Fair Value Measurements requires bifurcation of certain embedded derivative instruments in certain debt or equity instruments, and measurement at their fair value for accounting purposes. A holder redemption feature embedded in the Company’s note payable requires bifurcation from its host instrument and is accounted for as a freestanding derivative. The Company held no derivative financial instruments at December 31, 2021. Research and Development Costs Research and development costs are charged to expense as incurred and are comprised of fees paid to consultants and patent related costs. Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of December 31, 2021 and 2020, and at the date of adoption, the Company did not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2021 and 2020, the Company has not accrued any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation – Stock Compensation Net Income per Share Basic net income per share is calculated by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. The Company’s potentially dilutive securities which include primarily warrants, have been included in the computation of diluted net income per share for the twelve-month periods ended December 31, 2021 and 2020. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Basic and Diluted Earnings per Share Net Income Weighted Per Share Basic EPS Income available to common stockholders $ 3,586,034 482,826 $ 7.43 Diluted EPS Effect of warrants convertible into common stock $ 3,586,034 $ 9,394,164 $ 0.38 Recent Accounting Standards During the year ended December 31, 2021, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Investment in Common Stock

Investment in Common Stock	12 Months Ended
	Dec. 31, 2021
Investment In Common Stock
Investment in Common Stock	Note 3. Investment in Common Stock In the third quarter of 2021, Cytocom announced the completion of its merger with Cleveland BioLabs, Inc. (“CBLI”) which resulted in the Company’s receipt of 1,150,000 common shares of CBLI, reflecting the Company’s retained minority interest in Cytocom. The merger was completed in July 2021. Subsequent to the merger, CBLI adopted a new corporate name, Statera BioPharma, Inc., with the ticker symbol “STAB” effective September 1, 2021. Cytocom emerged as a publicly traded entity following the merger with CBLI. The Company recorded the fair value of the 1,150,000 common shares of STAB at $ 5,761,500 upon the announcement of the merger between Cytocom and CBLI. The Company recognized non-operating income upon the receipt of the STAB common shares in the Statement of Operations during the third quarter of 2021. In accordance with the reporting requirements of FASB ASC Topic 321, “Investments Equity Securities”, the Company re-measured the fair value of the STAB common shares at $ 2.30 per share and recognized a change in market value of $ 3,116,500 as of December 31, 2021. At December 31, 2021 the fair value of the STAB common shares measured at $ 2,645,000 and is reflected as a current asset in the Balance Sheet.

Notes payable

Notes payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes payable	4. Notes payable As of December 31, 2021, the Company had $ 1,639,275 in notes payable to shareholders of record. During the twelve months ended December 31, 2021 and December 31, 2020, the Company issued zero 197,000 , respectively in new promissory notes. Notes Payable at December 31, 2021 and 2020: Schedule of Notes Payable 2021 2020 December 31, 2021 2020 Promissory notes issued between December 2014 and January 2015. Lender earns interest at 10 36 $ 70,000 $ 70,000 Promissory notes issued between May 2015 and June 2016 and matured between February 2017 and November 2018 2 10 $ 149,500 149,500 Promissory notes were issued in 2016. The notes accrue interest at 2 November 2017 and December 2017 $ 606,500 606,500 Promissory notes were issued in 2017 accrue interest at 2 % and matured between January 2018 and September 2018 . These notes are in default. $ 205,000 205,000 Promissory notes were issued in 2017 accrue interest at 2 % and matured in May 2018 . These notes are in default. $ 150,000 150,000 Promissory notes were issued in 2017 accrue interest at 2 % and matured between August 2018 and September 2018 . These notes are in default. $ 116,800 116,800 A promissory note for $ 425,000 was issued in October 2017 with an original issue discount of $ 70,000 and an annual interest rate of 22 % on all outstanding balances. The note was in default, which triggered certain penalties, resulting in an outstanding balance of $ 454,032 . The original noteholder entered into a Note Purchase Agreement in November 2020, in the amount of $ 697,600 , reflecting the total principal, interest and penalties, and transferred the note to Global Reverb Corp., an entity wholly owned by the Company’s former Chief Executive Officer and former director, Noreen Griffin. During the first quarter of 2021, Global Reverb Corp. sold 50% of the value of the note to another investor. - 454,032 Promissory notes were issued in 2017 accrue interest at 2 $ 105,500 105,500 Promissory notes were issued in the 2018 accrue interest at 2 % and matured between May 2018 and January 2019 . These notes are in default. $ 47,975 47,975 Promissory notes were issued in 2018 accrue interest at 2 % and matured between July 2018 and October 2018 . These notes include warrants between 1,000 and 5,000 shares with an exercise price of $ 5 . These notes are in default. $ 65,000 65,000 Promissory notes were issued in 2018. The notes accrue interest at 2 August 2019 and January 2019 60,000 500,000 0.05 $ 118,000 118,000 Promissory notes were issued in 2018. The notes accrue interest at 2 January 2019 and November 2019 200 39,500 5 40 $ 323,855 323,855 Promissory note was issued to a related party in the first quarter of 2019. The note accrues interest at 2 July 2019 4,600 5 $ 23,000 23,000 Promissory note was issued in the first quarter of 2019. The note accrues interest at 6 February 2020 $ 231,478 231,478 Promissory note was issued in the second quarter of 2019 accrues interest at 2 July 2019 10,000 5 $ 10,000 10,000 Promissory note issued in October 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15 % per annum, with $ 1,875 due in monthly interest payments, and matured on April 30, 2021 . The note is in default. $ 150,000 150,000 Promissory note issued in the third quarter of 2020 accrued interest at 12 August 2021 54,312 5,402 - 53,000 Promissory notes issued in the first quarter of 2021 in connection with a Note Purchase Agreement with a previous note holder. The new notes reflect all principal, interest and penalties associated with the original instrument. These notes accrue interest at 5 % and a penalty rate of 7 %. The holder of $ 348,800 of these notes (Global Reverb Corp.) is an entity wholly owned by the Company’s former Chief Executive Officer that is also a former director of the Company. These notes are in default and mature in March 2022 . $ 697,600 - Notes Payable 3,070,208 2,879,640 Less: Original issue discount on notes payable and warrants issued with notes. - (34,789 ) Total $ 3,070,208 $ 2,844,851 As of December 31, 2021 and 2020, the Company had accrued $ 564,300 and $ 635,217 in unpaid interest and default penalties. Redstart Holdings Corp. In the first quarter 2020, the Company issued a Convertible Promissory Note to Redstart Holdings Corp. (“Redstart”) in the principal amount of $ 53,000 March 30, 2021 12 3,180 6,893 8.15 The conversion price as defined in the original note agreement equaled 61% multiplied by the lowest trading price for the common stock during the 20 Geneva Roth Remark Holdings, Inc. During the second and third quarters of 2020, the Company issued three Convertible Promissory Notes aggregating $ 144,000 12 The conversion price as defined in the original note agreement equaled 61% multiplied by the lowest trading price for the common stock during the 20 During the fourth quarter of 2020, GRRH converted $ 91,000 5,460 12,034 8.02 During the first quarter of 2021, GRRH converted the balance of the notes and the Company issued 5,402 10.40 53,000 3,480 2020 Gain on Settlement of Debt In 2020 the Company and Cytocom entered into an agreement for the Company to sublicense LDN and MENK for emerging markets to Cytocom. Pursuant to the agreement, effective September 30, 2020 the Company assigned certain notes payable aggregating principal amount of $ 2,728,731 495,409

Derivative Liability

Derivative Liability	12 Months Ended
	Dec. 31, 2021
Derivative Liability
Derivative Liability	5. Derivative Liability As of December 31, 2020 the fair value of the outstanding derivative liability was $ 1,254,444 Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions Year ended December 31, 2020 Volatility 178.65% Risk-free interest rate 1.0% Expected dividends na Expected term (years) .25 1.00 The Company determined the fair values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following three levels of inputs may be used to measure fair value: Level 1 Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company uses Level 3 inputs to estimate the fair value of its derivative liabilities. The following schedule summarizes the valuation of financial instruments at fair value in the balance sheets as of December 31, 2021: Schedule of Valuation of Financial Instruments Fair Value Measurements as of Level 1 Level 2 Level 3 Assets Fair value of common stock $ 2,645,000 - - Liabilities - - -

Common Stock and Common Stock W

Common Stock and Common Stock Warrants	12 Months Ended
	Dec. 31, 2021
Common Stock And Common Stock Warrants
Common Stock and Common Stock Warrants	6. Common Stock and Common Stock Warrants Each holder of common stock is entitled to vote on all shareholder matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. As of December 31, 2021, and 2020, the Company was authorized to issue 750,000,000 and 500,000,000 common shares, respectively, at a par value of $ 0.0001 per share. As of December 31, 2021, and 2020, the Company had 483,714 and 476,504 shares of common stock outstanding, respectively. Common Stock Warrants The Company did not issue or modify any warrants in the twelve-month period ended December 31, 2021. When the Company sells its stock to stockholders for cash, it periodically issues common stock warrants to the investors at prices agreed at the date of the original sale. The Company incurs a cost for the rights attached to the warrants, which is calculated using the Black-Scholes Model and is reported in the Statements of Operations in the period of issuance. A summary of outstanding warrants as of December 31, 2021 follows: Summary of Outstanding Warrants Expiration Date Number of Exercise Price Remaining First Quarter 2022 150 $ 200 .25 Second Quarter 2022 1,750 $ 150 .50 Third Quarter 2022 1,650 $ 50 100 .75 Fourth Quarter 2022 9,811 $ 80 290 1.00 First Quarter 2023 1,204,000 $ 5 40 1.25 Second Quarter 2023 802,000 $ 5 200 1.50 Third Quarter 2023 7,521,500 $ 5 100 1.75 Fourth Quarter 2023 6,024,300 $ 2 5 2.00 First Quarter 2024 3,660,000 $ 5 2.25 Second Quarter 2024 800,000 $ 5 2.50 Third Quarter 2028 3,000 $ 70 7.00 Second Quarter 2032 28,995 $ 10 70 10.75 20,057,156 $ 2 - 290 Following is a summary of outstanding stock warrants activity for the twelve months ended December 31, 2021 and 2020: Schedule of Outstanding Stock Warrants Number of Exercise Weighted Warrants as of December 31, 2019 20,083,335 $ 0.05 500 $ 4.21 Issued - - - Expired and forfeited (2,300 ) $ 100 500 $ 195.65 Exercised - - - Warrants as of December 31, 2020 20,081,035 $ 0.05 200 $ 4.22 Issued - - - Expired and forfeited (23,873 ) $ 14 200 $ 144.78 Exercised - - - Warrants as of December 31, 2021 20,057,162 $ 2 290 $ 5.21

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes There was no income tax expense reflected in the results of operations for the years ended December 31, 2021 and 2020. As of December 31, 2021, the Company had federal and state net operating loss carryforwards of $ 91,856,000 which may be used to offset future taxable income. Approximately $ 64,629,000 will expire in 2033 while $27,227,000 will be limited to 80% of taxable income but will not expire . The tax effects of temporary differences which give rise to deferred tax assets (liabilities) are summarized as follows: Deferred tax assets: Schedule of Deferred Tax Assets 2021 2020 Net operating losses $ 23,281,000 $ 19,892,000 Accrued expenses 21,000 - Stock based compensation - 39,284,000 Amortization, depreciation, and impairment - 4,178,000 Capitalization of start-up costs for tax purposes - 1,145,000 Gain/(loss) on conversion of debt ,000 713,000 Total deferred tax assets 23,302,000 65,212,000 Valuation allowance (23,302,000 ) (65,212,000 ) Total deferred tax assets, net $ - $ - In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the realization of future taxable income during the periods in which those temporary differences become deductible. Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding realizability. Schedule of Income Taxes Net Operating Loss For the year ended December 31, 2021 2020 Statutory federal tax rate 21.00 % 21.00 % State rate net of federal 6.69 % 0.00 % Permanent differences 11.35 % 4.94 % Prior period adjustment 1,142.33 % 2.63 % Valuation allowance (1,181,38 )% (21.00 )% Provision for income taxes - - The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of December 31, 2021, and 2020, the Company had no unrecognized tax benefits. There were no changes in the Company’s unrecognized tax benefits during the years ended December 31, 2021 and 2020. The Company did not recognize any interest or penalties during fiscal 2021 or 2020 related to unrecognized tax benefits. Tax years 2018-2021 remain open to examination for federal income tax purposes and by other taxing jurisdictions to which the Company is subject.

Licenses and Supply Agreements

Licenses and Supply Agreements	12 Months Ended
	Dec. 31, 2021
Licenses And Supply Agreements
Licenses and Supply Agreements	8. Licenses and Supply Agreements Forte Animal Health, Inc. On July 8, 2021, the Company amended the license agreement (the “Amended License Agreement”) with Forte Animal Health Inc. (“Forte”) dated February 27, 2020. Under the Amended License Agreement, the Company granted Forte an exclusive license to develop and commercialize pharmaceutical products consisting of Lodonal and MENK for use in veterinary applications for all indications world-wide. Milestone payments and royalties are defined in the agreement based on development and royalties are based on sales during the license period. The Initial License Fee includes the assumption of certain Company defaulted Notes and other liabilities. The note holders and vendors associated with the assigned liabilities have not yet assigned their rights to Forte. Consideration for Amended License Agreement with Forte at December 31, 2021 Schedule of Consideration Consideration / Assumption of: Notes in Default $ 2,040,006 Accounts payable and accruals 338,909 Past Due Employee Obligations 786,177 Total anticipated Consideration $ 4,642,776 Recognized through December 31, 2020 (3,302,209 ) Total Consideration to be Recognize Upon Execution $ 3,165,092 The documentation and sign off, of the Forte license, have yet to be executed by the individual lenders that will be required to provide their sign-off and approval for the transfer of these notes. As such the accompanying financial statements do not reflect any gain on sale. Until such time as the transaction is completed Forte does not have clear title and interest to the veterinary rights. Forte has agreed to make payments to the Company in connection with this agreement as follows: ● Initial License Fee, upon the assignment of certain Company Notes Payable. ● Development Milestone Payments upon the occurrence of the identified events, one-time, non-creditable, non-refundable milestone payments of $ 100,000 ● Commercial Milestone Payments upon reaching the mutually agreed aggregate net sales. Forte will pay one-time, non-creditable, non-refundable milestone payments to be negotiated and addressed in a separate Amendment later. ● Royalties during the royalty term (generally 15 Schedule of Royalty Rate Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 % As of December 31, 2021, this license agreement has not been executed as Forte has failed to fund the consideration defined in the agreement. To date the Company has not received any payments under the terms of this agreement. Cytocom On May 13, 2020, the Company and Cytocom entered into an Amendment to The Second Amendment to The License Agreement (“Third Amendment”) that was effective December 31, 2018. The sublicense provides Cytocom with the Company’s previously licensed rights for LDN and MENK in Emerging Markets. Original terms for consideration for the sublicense were not finalized until August 12, 2020, at which time Cytocom and the Company signed a letter agreement in which Cytocom agreed to assume a combination of defaulted notes plus certain other liabilities. Such terms were amended, and the Company agreed to transfer all the rights, title, and interest to Cytocom in technology licensed from Penn State Research Foundation (“PSU”) in exchange for Cytocom assuming all past due and future obligations under the PSU license. While the Company formalized the agreement to assign all outstanding liabilities due to PSU, a vendor of the Company, PSU did not consent to the assignment of the payables to Cytocom. As of December 31, 2021, the Company had no In the third quarter of 2020, the Company received a Notice of Default (“Notice”) from Cytocom relating to the sublicensing transaction. The Company disputes the validity of the Notice on the basis that Cytocom has failed to execute on their consideration for the license. On July 20, 2021 the Notice of Default was rescinded. On July 20, 2021, Cytocom and the Company agreed to modify the terms of the original sublicense. The renegotiated terms are presented below. The assignment of the Notes in Default was fully executed in the third quarter of 2020 with the transfer of the notes upon the creditors’ signoff. The Company recognized a gain upon the assignment of these notes in the third quarter of 2020. Cytocom has not completed the assumption of the remaining liabilities. Consideration for May 13, 2020 License to Cytocom at December 31, 2021 Consideration / Assumption of: Notes in Default $ 3,302,209 Accounts payable and accruals 230,000 Past Due Employee Obligations 1,110,567 Total anticipated Consideration $ 4,642,776 Recognized through December 31, 2020 (3,302,209 ) To Be Recognized upon Execution $ 1,340,567 As of December 31, 2021, the Notes transaction has not been fully executed. The Notes in default have been assigned and the transfer signed off by the creditors, but Cytocom still has not completed the assumption of the agreed upon obligations.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Distribution Agreements in Nigeria In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The first deliveries under the agreement took place in February 2018. Under the original agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment On April 18, 2018, AHAR Pharma transferred its rights under the Distribution Agreement to Fidson Healthcare Plc (“Fidson”), and Fidson signed an exclusive distribution agreement with the Company to distribute Lodonal™. There were no shipments under this agreement during the years ended December 31, 2020 and 2019. There were also no discussions with Fidson regarding the Distribution Agreement in 2020 or 2019. Contract Manufacturing Agreements On October 25, 2016, the Company and Acromax Dominicana, SA (“Acromax”), which is based in the Dominican Republic, entered into a contract for manufacturing of LDN tablets, capsules and/or creams (“Agreement”). Subject to the terms and conditions of the Agreement, Acromax will obtain all necessary licenses and permits to carry out the manufacturing and packaging of LDN in exchange for a fixed fee per tablet plus an additional fee for packaging, shipping and customs clearance. The Agreement has an initial term of five years unless terminated by either party in accordance with the terms.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions Board and Officer Transactions Kevin Phelps, the Company’s Chief Executive & Financial Officer, and a member of the board of directors, has earned board compensation of $ 5,000 a month during 2021 and 2020. Mr. Phelps has unpaid board fees of $ 185,000 125,000 240,000 400,000 Dr. Roscoe Moore, the chairman of the board of directors, is entitled to receive compensation of $ 5,000 215,250 155,250

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events On January 27, 2022, the Company was named as defendant in a lawsuit filed in the Superior Court of the State of Arizona for the County of Maricopa by Mr. Ira Gaines. The lawsuit is based on claims for breach of contract alleging the failure by the Company to make required payments of principal and interest arising out of the secured promissory note dated October 1, 2019 made by the Company in favor of Mr. Gaines in the original principal amount of $ 150,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“GAAP”) and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of the Company’s investment in the common stock of Statera BioPharma (“STAB”) is measured based on the quoted per share price as reported on NASDAQ and is a level 1 asset. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.
Derivative Financial Instruments	Derivative Financial Instruments FASB ASC 815, Fair Value Measurements requires bifurcation of certain embedded derivative instruments in certain debt or equity instruments, and measurement at their fair value for accounting purposes. A holder redemption feature embedded in the Company’s note payable requires bifurcation from its host instrument and is accounted for as a freestanding derivative. The Company held no derivative financial instruments at December 31, 2021.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are comprised of fees paid to consultants and patent related costs.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of December 31, 2021 and 2020, and at the date of adoption, the Company did not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2021 and 2020, the Company has not accrued any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation – Stock Compensation
Net Income per Share	Net Income per Share Basic net income per share is calculated by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. The Company’s potentially dilutive securities which include primarily warrants, have been included in the computation of diluted net income per share for the twelve-month periods ended December 31, 2021 and 2020. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Basic and Diluted Earnings per Share Net Income Weighted Per Share Basic EPS Income available to common stockholders $ 3,586,034 482,826 $ 7.43 Diluted EPS Effect of warrants convertible into common stock $ 3,586,034 $ 9,394,164 $ 0.38
Recent Accounting Standards	Recent Accounting Standards During the year ended December 31, 2021, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Organization and Description _2

Organization and Description of Business (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Income Statement	Schedule of Income Statement Gain on settlement of debt and liabilities $ 711,892 Receipt of common shares 5,761,500 Change in market value of common shares (3,116,500 ) Gain on reversal of derivative liability 1,178,230 Non-operating gains $ 4,535,122

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Basic and Diluted Earnings per Share	A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Basic and Diluted Earnings per Share Net Income Weighted Per Share Basic EPS Income available to common stockholders $ 3,586,034 482,826 $ 7.43 Diluted EPS Effect of warrants convertible into common stock $ 3,586,034 $ 9,394,164 $ 0.38

Notes payable (Tables)

Notes payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes Payable at December 31, 2021 and 2020: Schedule of Notes Payable 2021 2020 December 31, 2021 2020 Promissory notes issued between December 2014 and January 2015. Lender earns interest at 10 36 $ 70,000 $ 70,000 Promissory notes issued between May 2015 and June 2016 and matured between February 2017 and November 2018 2 10 $ 149,500 149,500 Promissory notes were issued in 2016. The notes accrue interest at 2 November 2017 and December 2017 $ 606,500 606,500 Promissory notes were issued in 2017 accrue interest at 2 % and matured between January 2018 and September 2018 . These notes are in default. $ 205,000 205,000 Promissory notes were issued in 2017 accrue interest at 2 % and matured in May 2018 . These notes are in default. $ 150,000 150,000 Promissory notes were issued in 2017 accrue interest at 2 % and matured between August 2018 and September 2018 . These notes are in default. $ 116,800 116,800 A promissory note for $ 425,000 was issued in October 2017 with an original issue discount of $ 70,000 and an annual interest rate of 22 % on all outstanding balances. The note was in default, which triggered certain penalties, resulting in an outstanding balance of $ 454,032 . The original noteholder entered into a Note Purchase Agreement in November 2020, in the amount of $ 697,600 , reflecting the total principal, interest and penalties, and transferred the note to Global Reverb Corp., an entity wholly owned by the Company’s former Chief Executive Officer and former director, Noreen Griffin. During the first quarter of 2021, Global Reverb Corp. sold 50% of the value of the note to another investor. - 454,032 Promissory notes were issued in 2017 accrue interest at 2 $ 105,500 105,500 Promissory notes were issued in the 2018 accrue interest at 2 % and matured between May 2018 and January 2019 . These notes are in default. $ 47,975 47,975 Promissory notes were issued in 2018 accrue interest at 2 % and matured between July 2018 and October 2018 . These notes include warrants between 1,000 and 5,000 shares with an exercise price of $ 5 . These notes are in default. $ 65,000 65,000 Promissory notes were issued in 2018. The notes accrue interest at 2 August 2019 and January 2019 60,000 500,000 0.05 $ 118,000 118,000 Promissory notes were issued in 2018. The notes accrue interest at 2 January 2019 and November 2019 200 39,500 5 40 $ 323,855 323,855 Promissory note was issued to a related party in the first quarter of 2019. The note accrues interest at 2 July 2019 4,600 5 $ 23,000 23,000 Promissory note was issued in the first quarter of 2019. The note accrues interest at 6 February 2020 $ 231,478 231,478 Promissory note was issued in the second quarter of 2019 accrues interest at 2 July 2019 10,000 5 $ 10,000 10,000 Promissory note issued in October 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15 % per annum, with $ 1,875 due in monthly interest payments, and matured on April 30, 2021 . The note is in default. $ 150,000 150,000 Promissory note issued in the third quarter of 2020 accrued interest at 12 August 2021 54,312 5,402 - 53,000 Promissory notes issued in the first quarter of 2021 in connection with a Note Purchase Agreement with a previous note holder. The new notes reflect all principal, interest and penalties associated with the original instrument. These notes accrue interest at 5 % and a penalty rate of 7 %. The holder of $ 348,800 of these notes (Global Reverb Corp.) is an entity wholly owned by the Company’s former Chief Executive Officer that is also a former director of the Company. These notes are in default and mature in March 2022 . $ 697,600 - Notes Payable 3,070,208 2,879,640 Less: Original issue discount on notes payable and warrants issued with notes. - (34,789 ) Total $ 3,070,208 $ 2,844,851

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Liability
Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions	Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions Year ended December 31, 2020 Volatility 178.65% Risk-free interest rate 1.0% Expected dividends na Expected term (years) .25 1.00
Schedule of Valuation of Financial Instruments	The following schedule summarizes the valuation of financial instruments at fair value in the balance sheets as of December 31, 2021: Schedule of Valuation of Financial Instruments Fair Value Measurements as of Level 1 Level 2 Level 3 Assets Fair value of common stock $ 2,645,000 - - Liabilities - - -

Common Stock and Common Stock_2

Common Stock and Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Common Stock And Common Stock Warrants
Summary of Outstanding Warrants	A summary of outstanding warrants as of December 31, 2021 follows: Summary of Outstanding Warrants Expiration Date Number of Exercise Price Remaining First Quarter 2022 150 $ 200 .25 Second Quarter 2022 1,750 $ 150 .50 Third Quarter 2022 1,650 $ 50 100 .75 Fourth Quarter 2022 9,811 $ 80 290 1.00 First Quarter 2023 1,204,000 $ 5 40 1.25 Second Quarter 2023 802,000 $ 5 200 1.50 Third Quarter 2023 7,521,500 $ 5 100 1.75 Fourth Quarter 2023 6,024,300 $ 2 5 2.00 First Quarter 2024 3,660,000 $ 5 2.25 Second Quarter 2024 800,000 $ 5 2.50 Third Quarter 2028 3,000 $ 70 7.00 Second Quarter 2032 28,995 $ 10 70 10.75 20,057,156 $ 2 - 290
Schedule of Outstanding Stock Warrants	Following is a summary of outstanding stock warrants activity for the twelve months ended December 31, 2021 and 2020: Schedule of Outstanding Stock Warrants Number of Exercise Weighted Warrants as of December 31, 2019 20,083,335 $ 0.05 500 $ 4.21 Issued - - - Expired and forfeited (2,300 ) $ 100 500 $ 195.65 Exercised - - - Warrants as of December 31, 2020 20,081,035 $ 0.05 200 $ 4.22 Issued - - - Expired and forfeited (23,873 ) $ 14 200 $ 144.78 Exercised - - - Warrants as of December 31, 2021 20,057,162 $ 2 290 $ 5.21

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Schedule of Deferred Tax Assets 2021 2020 Net operating losses $ 23,281,000 $ 19,892,000 Accrued expenses 21,000 - Stock based compensation - 39,284,000 Amortization, depreciation, and impairment - 4,178,000 Capitalization of start-up costs for tax purposes - 1,145,000 Gain/(loss) on conversion of debt ,000 713,000 Total deferred tax assets 23,302,000 65,212,000 Valuation allowance (23,302,000 ) (65,212,000 ) Total deferred tax assets, net $ - $ -
Schedule of Income Taxes Net Operating Loss	Schedule of Income Taxes Net Operating Loss For the year ended December 31, 2021 2020 Statutory federal tax rate 21.00 % 21.00 % State rate net of federal 6.69 % 0.00 % Permanent differences 11.35 % 4.94 % Prior period adjustment 1,142.33 % 2.63 % Valuation allowance (1,181,38 )% (21.00 )% Provision for income taxes - -

Licenses and Supply Agreements

Licenses and Supply Agreements (Tables)	12 Months Ended
	Dec. 31, 2021
Licenses And Supply Agreements
Schedule of Consideration	Consideration for Amended License Agreement with Forte at December 31, 2021 Schedule of Consideration Consideration / Assumption of: Notes in Default $ 2,040,006 Accounts payable and accruals 338,909 Past Due Employee Obligations 786,177 Total anticipated Consideration $ 4,642,776 Recognized through December 31, 2020 (3,302,209 ) Total Consideration to be Recognize Upon Execution $ 3,165,092 Consideration / Assumption of: Notes in Default $ 3,302,209 Accounts payable and accruals 230,000 Past Due Employee Obligations 1,110,567 Total anticipated Consideration $ 4,642,776 Recognized through December 31, 2020 (3,302,209 ) To Be Recognized upon Execution $ 1,340,567
Schedule of Royalty Rate	Schedule of Royalty Rate Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 %

Schedule of Income Statement (D

Schedule of Income Statement (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Gain on settlement of debt and liabilities	$ 711,892
Receipt of common shares	5,761,500
Change in market value of common shares	(3,116,500)
Gain on reversal of derivative liability	1,178,230	$ (373,584)
Non-operating gains	$ 4,535,122

Organization and Description _3

Organization and Description of Business (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 493,885	$ 9,971
Working capital	7,948,256
Stockholders' Equity Attributable to Parent	7,948,256	11,666,981	$ 13,688,621
Net Income (Loss) Attributable to Parent	3,586,034	1,588,617
Nonoperating Gains (Losses)	4,535,122
Net income	3,586,034	1,588,617
Gains (losses) on restructuring of debt	$ 711,892	$ 3,502,280

Schedule of Basic and Diluted E

Schedule of Basic and Diluted Earnings per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Basic EPS, Income available to common stockholders	$ 3,586,034	$ 1,588,617
Basic EPS, Weighted average common shares, basic	482,826	461,190
Basic earnings per share	$ 7.43	$ 3.44
Diluted EPS, Effect of warrants convertible into common stock	$ 3,586,034
Diluted EPS, Weighted average common shares, diluted	9,394,164
Diluted earnings per share	$ 0.38	$ 0.11

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	Dec. 31, 2021USD ($)
Accounting Policies [Abstract]
Cash at federal deposit	$ 250,000

Investment in Common Stock (Det

Investment in Common Stock (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Fair value of common shares		$ 2,645,000
Cleveland Bio Labs Inc [Member]
Stock Issued During Period, Shares, Acquisitions	1,150,000
Stock Issued During Period, Value, Acquisitions	$ 5,761,500
Stratera Bio Pharma Inc [Member]
Share Price		$ 2.30
Change in fair value, gain (loss)		$ 3,116,500
Fair value of common shares		$ 2,645,000

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Oct. 31, 2019	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2021	Dec. 31, 2020	Oct. 31, 2017
Short-term Debt [Line Items]
Notes Payable									$ 3,070,208	$ 2,879,640
Less: Original issue discount on notes payable and warrants issued with notes.										(34,789)
Total									3,070,208	2,844,851
Notes Payable One [Member]
Short-term Debt [Line Items]
Notes Payable									70,000	70,000
Notes Payable Two [Member]
Short-term Debt [Line Items]
Notes Payable									149,500	149,500
Notes Payable Three [Member]
Short-term Debt [Line Items]
Notes Payable									606,500	606,500
Debt instrument, maturity date, description								November 2017 and December 2017
Notes Payable Four [Member]
Short-term Debt [Line Items]
Notes Payable									205,000	205,000
Debt instrument, maturity date, description							January 2018 and September 2018
Notes Payable Five [Member]
Short-term Debt [Line Items]
Notes Payable									150,000	150,000
Debt instrument, maturity date, description							May 2018
Notes Payable Six [Member]
Short-term Debt [Line Items]
Notes Payable									116,800	116,800
Debt instrument, maturity date, description							August 2018 and September 2018
Notes Payable Seven [Member]
Short-term Debt [Line Items]
Notes Payable										454,032
Total											$ 425,000
Notes Payable Eight [Member]
Short-term Debt [Line Items]
Notes Payable									105,500	105,500
Notes Payable Nine [Member]
Short-term Debt [Line Items]
Notes Payable									47,975	47,975
Debt instrument, maturity date, description						May 2018 and January 2019
Notes Payable Ten [Member]
Short-term Debt [Line Items]
Notes Payable									65,000	65,000
Debt instrument, maturity date, description						July 2018 and October 2018
Notes Payable Eleven [Member]
Short-term Debt [Line Items]
Notes Payable									118,000	118,000
Debt instrument, maturity date, description						August 2019 and January 2019
Notes Payable Twelve [Member]
Short-term Debt [Line Items]
Notes Payable									323,855	323,855
Debt instrument, maturity date, description						January 2019 and November 2019
Notes Payable Thirteen [Member]
Short-term Debt [Line Items]
Notes Payable									23,000	23,000
Debt instrument, maturity date, description					July 2019
Notes Payable Fourteen [Member]
Short-term Debt [Line Items]
Notes Payable									231,478	231,478
Debt instrument, maturity date, description					February 2020
Notes Payable Fifteen [Member]
Short-term Debt [Line Items]
Notes Payable									10,000	10,000
Debt instrument, maturity date, description				July 2019
Notes Payable Sixteen [Member]
Short-term Debt [Line Items]
Notes Payable									150,000	150,000
Debt instrument, maturity date, description	April 30, 2021
Notes Payable Seventeen [Member]
Short-term Debt [Line Items]
Notes Payable										53,000
Debt instrument, maturity date, description			August 2021
Notes Payable Eighteen [Member]
Short-term Debt [Line Items]
Notes Payable									$ 697,600
Debt instrument, maturity date, description		March 2022

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical)

Oct. 31, 2019USD ($)

Feb. 28, 2021shares

Jan. 31, 2015Integer

Mar. 31, 2021USD ($)

Sep. 30, 2020USD ($)

Jun. 30, 2019$ / sharesshares

Mar. 31, 2019

Dec. 31, 2018$ / sharesshares

Dec. 31, 2017

Dec. 31, 2016

Jun. 30, 2016

Dec. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)

Dec. 31, 2019$ / sharesshares

Oct. 31, 2017USD ($)

Short-term Debt [Line Items]

Notes payable | $

$ 3,070,208

$ 2,844,851

Class of warrant or right, outstanding

20,057,156

Minimum [Member]

Short-term Debt [Line Items]

Class of warrant or right, exercise price | $ / shares

$ 2

Maximum [Member]

Short-term Debt [Line Items]

Class of warrant or right, exercise price | $ / shares

$ 290

Notes Payable One [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

10.00%

Number of installments | Integer

36

Notes Payable Two [Member] | Lenders [Member]

Short-term Debt [Line Items]

Debt instrument maturity date description

February 2017 and November 2018

Notes Payable Two [Member] | Lenders [Member] | Minimum [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Notes Payable Two [Member] | Lenders [Member] | Maximum [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

10.00%

Notes Payable Three [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

November 2017 and December 2017

Notes Payable Four [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

January 2018 and September 2018

Notes Payable Five [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

May 2018

Notes Payable Six [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

August 2018 and September 2018

Notes Payable Seven [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

22.00%

Notes payable | $

$ 425,000

Debt instrument, unamortized discount | $

70,000

Notes Payable Seven [Member] | Note Purchase Agreement [Member]

Short-term Debt [Line Items]

Notes payable | $

454,032

Debt Instrument, Face Amount | $

$ 697,600

Notes Payable Eight [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Notes Payable Nine [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

May 2018 and January 2019

Notes Payable Ten [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July 2018 and October 2018

Class of warrant or right, exercise price | $ / shares

$ 5

Notes Payable Ten [Member] | Minimum [Member]

Short-term Debt [Line Items]

Class of warrant or right, outstanding

1,000

Notes Payable Ten [Member] | Maximum [Member]

Short-term Debt [Line Items]

Class of warrant or right, outstanding

5,000

Notes Payable Eleven [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

August 2019 and January 2019

Notes Payable Eleven [Member] | Minimum [Member]

Short-term Debt [Line Items]

Class of warrant or right, outstanding

60,000

Class of warrant or right, exercise price | $ / shares

$ 0.05

Notes Payable Eleven [Member] | Maximum [Member]

Short-term Debt [Line Items]

Class of warrant or right, outstanding

500,000

Notes Payable Twelve [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

January 2019 and November 2019

Notes Payable Twelve [Member] | Minimum [Member]

Short-term Debt [Line Items]

Class of warrant or right, outstanding

200

Class of warrant or right, exercise price | $ / shares

$ 5

Notes Payable Twelve [Member] | Maximum [Member]

Short-term Debt [Line Items]

Class of warrant or right, outstanding

39,500

Class of warrant or right, exercise price | $ / shares

$ 40

Notes Payable Thirteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July 2019

Class of warrant or right, outstanding

4,600

Class of warrant or right, exercise price | $ / shares

$ 5

Notes Payable Fourteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

6.00%

Debt instrument maturity date description

February 2020

Notes Payable Fifteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July 2019

Class of warrant or right, outstanding

10,000

Class of warrant or right, exercise price | $ / shares

$ 5

Notes Payable Sixteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

15.00%

Debt instrument maturity date description

April 30, 2021

Debt instrument, periodic payment | $

$ 1,875

Notes Payable Seventeen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

12.00%

Debt instrument maturity date description

August 2021

Derivative liability | $

$ 54,312

Debt converted shares

5,402

Notes Payable Eighteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

5.00%

Debt instrument maturity date description

March 2022

Debt penalty percentage

7.00%

Notes Payable Eighteen [Member] | Note Purchase Agreement [Member]

Short-term Debt [Line Items]

Debt Instrument, Face Amount | $

$ 348,800

Notes payable (Details Narrativ

Notes payable (Details Narrative)	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2020USD ($)Integer	Jun. 30, 2020USD ($)Integer	Mar. 31, 2020USD ($)Integer$ / sharesshares	Dec. 31, 2021USD ($)	Oct. 31, 2020USD ($)
Short-term Debt [Line Items]
Notes payable		$ 2,879,640				$ 3,070,208
Accrued unpaid interest and default penalties		635,217				564,300
Three Convertible Promissory Notes [Member] | Geneva Roth Remark Holdings [Member]
Short-term Debt [Line Items]
Interest rate			12.00%	12.00%
Redstart Holdings Corp. [Member]
Short-term Debt [Line Items]
Principal amount					$ 53,000
Debt Maturity date					Mar. 30, 2021
Interest rate					12.00%
Accurued interest							$ 3,180
Debt conversion shares | shares					6,893
Conversion price per share | $ / shares					$ 8.15
Debt conversion description					The conversion price as defined in the original note agreement equaled 61% multiplied by the lowest trading price for the common stock during the 20-trading day period ending on the latest complete trading day prior to the conversion date
Trading days | Integer					20
Geneva Roth Remark Holdings [Member]
Short-term Debt [Line Items]
Principal amount		91,000
Accurued interest	$ 3,480	$ 5,460
Debt conversion amount	$ 53,000
Stock issued during period, shares | shares	5,402	12,034
Price per share | $ / shares	$ 10.40	$ 8.02
Geneva Roth Remark Holdings [Member] | Three Convertible Promissory Notes [Member]
Short-term Debt [Line Items]
Debt conversion description			The conversion price as defined in the original note agreement equaled 61% multiplied by the lowest trading price for the common stock during the 20-trading day period ending on the latest complete trading day prior to the conversion date	The conversion price as defined in the original note agreement equaled 61% multiplied by the lowest trading price for the common stock during the 20-trading day period ending on the latest complete trading day prior to the conversion date.
Trading days | Integer			20	20
Debt conversion amount			$ 144,000	$ 144,000
Cytocom [Member]
Short-term Debt [Line Items]
Principal amount			2,728,731
Accurued interest			$ 495,409
Shareholders [Member]
Short-term Debt [Line Items]
Notes payable						1,639,275
Promissory Notes [Member]
Short-term Debt [Line Items]
Notes payable		$ 197,000				$ 0

Schedule of Estimated Fair Valu

Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions (Details) - Black Scholes Option Pricing Model [Member]	12 Months Ended
	Dec. 31, 2020
Measurement Input, Price Volatility [Member]
Credit Derivatives [Line Items]
Risk-free interest rate	178.65
Measurement Input, Risk Free Interest Rate [Member]
Credit Derivatives [Line Items]
Risk-free interest rate	1
Measurement Input, Expected Term [Member] | Minimum [Member]
Credit Derivatives [Line Items]
Expected term (years)	3 months
Measurement Input, Expected Term [Member] | Maximum [Member]
Credit Derivatives [Line Items]
Expected term (years)	1 year

Schedule of Valuation of Financ

Schedule of Valuation of Financial Instruments (Details)	Dec. 31, 2021USD ($)
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of common stock	$ 2,645,000
Liabilities
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of common stock
Liabilities
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of common stock
Liabilities

Derivative Liability (Details N

Derivative Liability (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Derivative Liability
Derivative liabilities		$ 1,254,444

Summary of Outstanding Warrants

Summary of Outstanding Warrants (Details)	Dec. 31, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Shares | shares	20,057,156
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 290
First Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	150
Exercise Price	$ 200
Remaining Life (years)	3 months
Second Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	1,750
Exercise Price	$ 150
Remaining Life (years)	6 months
Third Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	1,650
Remaining Life (years)	9 months
Third Quarter 2022 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 50
Third Quarter 2022 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 100
Fourth Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	9,811
Remaining Life (years)	1 year
Fourth Quarter 2022 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 80
Fourth Quarter 2022 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 290
First Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	1,204,000
Remaining Life (years)	1 year 3 months
First Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
First Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 40
Second Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	802,000
Remaining Life (years)	1 year 6 months
Second Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
Second Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 200
Third Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	7,521,500
Remaining Life (years)	1 year 9 months
Third Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
Third Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 100
Fourth Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	6,024,300
Remaining Life (years)	2 years
Fourth Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2
Fourth Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
First Quarter 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	3,660,000
Exercise Price	$ 5
Remaining Life (years)	2 years 3 months
Second Quarter 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	800,000
Exercise Price	$ 5
Remaining Life (years)	2 years 6 months
Third Quarter 2028 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	3,000
Exercise Price	$ 70
Remaining Life (years)	7 years
Second Quarter 2032 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	28,995
Remaining Life (years)	10 years 9 months
Second Quarter 2032 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 10
Second Quarter 2032 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 70

Schedule of Outstanding Stock W

Schedule of Outstanding Stock Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Shares Warrants, Beginning balance	20,081,035	20,083,335
Weighted Average Price, Beginning balance	$ 4.22	$ 4.21
Number of Shares Warrants, Issued
Exercise Price, Issued
Weighted Average Price, Issued
Number of Shares Warrants, Expired and forfeited	(23,873)	(2,300)
Weighted Average Price, Expired and forfeited	$ 144.78	$ 195.65
Number of Shares Warrants, Exercised
Exercise Price, Exercised
Weighted Average Price, Exercised
Number of Shares Warrants, Ending balance	20,057,162	20,081,035
Weighted Average Price, Ending balance	$ 5.21	$ 4.22
Minimum [Member]
Exercise Price, Beginning Balance	0.05	0.05
Exercise Price, Expired and forfeited	14	100
Exercise Price, Ending Balance	2	0.05
Maximum [Member]
Exercise Price, Beginning Balance	200	500
Exercise Price, Expired and forfeited	200	500
Exercise Price, Ending Balance	$ 290	$ 200

Common Stock and Common Stock_3

Common Stock and Common Stock Warrants (Details Narrative) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Common Stock And Common Stock Warrants
Common stock, shares authorized	750,000,000	500,000,000
Common stock, par or stated value per share	$ 0.0001	$ 0.0001
Common stock, shares, outstanding	483,714	476,504

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating losses	$ 23,281,000	$ 19,892,000
Accrued expenses	21,000
Stock based compensation		39,284,000
Amortization, depreciation, and impairment		4,178,000
Capitalization of start-up costs for tax purposes		1,145,000
Gain/(loss) on conversion of debt	0	713,000
Total deferred tax assets	23,302,000	65,212,000
Valuation allowance	(23,302,000)	(65,212,000)
Total deferred tax assets, net

Schedule of Income Taxes Net Op

Schedule of Income Taxes Net Operating Loss (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory federal tax rate	21.00%	21.00%
State rate net of federal	6.69%	0.00%
Permanent differences	11.35%	4.94%
Prior period adjustment	1142.33%	2.63%
Valuation allowance	(1181.38%)	(21.00%)
Provision for income taxes

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Expense (Benefit)		$ 0
Operating Loss Carryforwards	$ 91,856,000
Income Tax Examination, Description	2033
Operating Loss Carryforwards, Limitations on Use	$27,227,000 will be limited to 80% of taxable income but will not expire
Expire in Two Thousand Thirty Three [Member]
Operating Loss Carryforwards	$ 64,629,000

Schedule of Consideration (Deta

Schedule of Consideration (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Forte Animal Health, Inc. [Member]
Notes in Default	$ 2,040,006
Accounts payable and accruals	338,909
Past Due Employee Obligations	786,177
Total Consideration to be Recognize Upon Execution	3,165,092
Cytocom inc [Member]
Notes in Default	3,302,209
Accounts payable and accruals	230,000
Past Due Employee Obligations	1,110,567
Total anticipated Consideration	4,642,776
Recognized through December 31, 2020	(3,302,209)
Total Consideration to be Recognize Upon Execution	$ 1,340,567

Schedule of Royalty Rate (Detai

Schedule of Royalty Rate (Details)	Feb. 27, 2020
Less than 500,000,000 [Member]
Royalty Rate	2.00%
From 500,000,000 to less than 1,000,000,000 [Member]
Royalty Rate	4.00%
Greater than 1,000,000,000 [Member]
Royalty Rate	6.00%

Licenses and Supply Agreement_2

Licenses and Supply Agreements (Details Narrative) - USD ($)	Feb. 27, 2020	Dec. 31, 2021
Penn state university [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts payable, related parties		$ 0
License Agreement [Member] | Forte Animal Health, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable milestone payments	$ 100,000
Royalty term	15 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	1 Months Ended
	Oct. 31, 2013
Distribution Agreement AHAR Pharma [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply commitment, description	the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Kevin Phelps [Member]
Related Party Transaction [Line Items]
Officers compensation	$ 5,000
Unpaid cash compensation	185,000	$ 125,000
Cash compensation received	240,000
Accrued salaries	400,000
Roscoe Moore [Member]
Related Party Transaction [Line Items]
Officers compensation	5,000
Unpaid cash compensation	$ 215,250	$ 155,250

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jan. 27, 2022	Dec. 31, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Principal amount of notes payable		$ 3,070,208	$ 2,879,640
Subsequent Event [Member] | Mr Gaines [Member]
Subsequent Event [Line Items]
Principal amount of notes payable	$ 150,000